In this document, unless the context otherwise requires, the following terms shall have the meanings set out below. Certain other terms are explained in the section headed "Glossary of Technical Terms" in this document.

"Accountants' Report"	the Accountants' Report for the years ended December 31, 2023, 2024 and the six months ended June 30, 2025 prepared by the Reporting Accountants, the text of which is set out in Appendix I to this document;
"AFRC"	the Accounting and Financial Reporting Council of Hong Kong;
"Articles of Association" or "Articles"	the articles of association of our Company adopted on November 20, 2025, which shall become effective as of the date on which the H Shares are [**REDACTED**] on the Stock Exchange, as amended from time to time, a summary of which is set out in "Appendix V—Summary of Articles of Association" to this document;
"associate(s)"	has the meaning ascribed to it under the Listing Rules;
"Audit Committee"	the audit committee of our Board;
"Beijing Weidao"	Beijing Weidao Medical Technology Co., Ltd.* (北京微刀醫療科技有限公司), a limited company established in the PRC on September 2, 2021 and a direct wholly-owned subsidiary of our Company, which was subsequently deregistered on November 8, 2024;
"Board" or "Board of Directors"	the board of Directors of our Company;
"business day"	a day on which banks in Hong Kong are generally open for normal banking business to the public and which is not a Saturday, Sunday or public holiday in Hong Kong;

[**REDACTED**]

"Chengzhen Health"	Zhuhai Chengzhen Health Technology Partnership (Limited Partnership)* (珠海誠真健康科技合夥企業(有限合夥)), a limited partnership established in the PRC on April 4, 2018, which is owned as to 99% and 1% by China True Health Medical as its limited partner, and Renxiang Biotechnology as its general partner, respectively, and is one of our Controlling Shareholders;
"China", "Chinese Mainland" or "PRC"	The People's Republic of China, but for the purpose of this document and for geographical reference only and except where the context requires otherwise, references in this document to "China" and the "PRC" do not apply to Hong Kong, Macau and Taiwan;
"China True Health Medical"	China True Health Medical Technology Co., Ltd. (中國真健康醫療科技有限公司), a limited liability company established in Macau on May 31, 2019, which is owned as to 96.67% and 3.33% by Ms. Cheong and Mr. Cheong Kam Leng (張錦鈴), father of Ms. Cheong, respectively, and is one of our Controlling Shareholders;
"CIC"	China Insights Industry Consultancy Limited, a global market research and consulting company, which is an Independent Third Party;
"CIC Report"	an independent market research report commissioned by us and prepared by CIC for the purpose of this document;
"close associate(s)"	has the meaning ascribed to it under the Listing Rules;
"Companies Ordinance"	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) as amended, supplemented or otherwise modified from time to time;
"Companies (Winding Up and Miscellaneous Provisions) Ordinance"	the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time;

"Company", "our Company" or "the Company"	Guangdong True Health Medical Technology Development Co., Ltd. (廣東真健康醫療科技開發股份有限公司) (formerly known as True Health (Guangdong Hengqin) Medical Technology Co., Ltd.* (真健康(廣東橫琴)醫療科技有限公司)), a limited liability company established in the PRC on March 16, 2018 and subsequently converted into a joint stock company with limited liability on October 29, 2025;
"connected person(s)"	has the meaning ascribed to it under the Listing Rules;
"connected transaction(s)"	has the meaning ascribed to it under the Listing Rules;
"Controlling Shareholders"	has the meaning ascribed to it under the Listing Rules and unless the context otherwise requires, refers to Ms. Cheong, Renxiang Biotechnology, China True Health Medical, Shuimu Medical Technology, Renyang Biotechnology, Chengzhen Health, Jiarun Tongchuang, Jiarun Hechuang, Zhuhai Meijirui, Jiarun Xinchuang and Xinhui Runkang as further detailed in the section headed "Relationship with Our Controlling Shareholders";
"core connected person(s)"	has the meaning ascribed to it under the Listing Rules;
"Core Product"	has the meaning ascribed thereto under Chapter 18A of the Listing Rules and for the purpose of this document, our Core Product refers to our percutaneous puncture surgical robot, which comprises four models;
"Corporate Governance Code"	the Corporate Governance Code set out in Appendix C1 to the Listing Rules;
"COVID-19"	a viral respiratory disease caused by the severe acute respiratory syndrome coronavirus;
"CSDC"	China Securities Depositary and Clearing Corporation Limited (中國證券登記結算有限責任公司);
"CSRC"	the China Securities Regulatory Commission of the PRC (中國證券監督管理委員會);
"Director(s)"	the director(s) of our Company;

"Domestic Unlisted Share(s)"	ordinary share(s) in the share capital of our Company, with a nominal value of RMB1.00 each, which are not listed on any stock exchange;
"EIT"	the enterprise income tax;
"EIT Law"	the PRC Enterprise Income Tax Law (中華人民共和國企業所得税法), as enacted by the NPC on March 16, 2007 and effective on January 1, 2008, as amended, supplemented or otherwise modified from time to time;
"Extreme Conditions"	the occurrence of "extreme conditions" as announced by any government authority of Hong Kong due to serious disruption of public transport services, extensive flooding, major landslides, large-scale power outage or any other adverse conditions before Typhoon Signal No. 8 or above is replaced with Typhoon Signal No. 3 or below;

[**REDACTED**]

"Group", "our Group", "we", "our" or "us"	our Company and all of our subsidiaries or, where the context so requires, in respect of the period before our Company became the holding company of our present subsidiaries, the business operated by such subsidiaries or their predecessors (as the case may be);
"Guide"	the "Guide for New Listing Applicants" published by the Stock Exchange in November 2023 which took effect on January 1, 2024, as amended or supplemented or otherwise modified from time to time;

"H Share(s)"	ordinary share(s) in the share capital of our Company with nominal value of RMB1.00 each, which are to be [**REDACTED**] and [**REDACTED**] Hong Kong dollars and for which an application has been made for [**REDACTED**] and [**REDACTED**] on the Stock Exchange;

[**REDACTED**]

"Haikou Weidao"	Haikou Weidao Medical Technology Co., Ltd.* (海口微刀醫療科技有限公司), a limited company established in the PRC on December 23, 2021 and an indirect wholly-owned subsidiary of our Company, which was subsequently deregistered on January 4, 2024;
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong;

[**REDACTED**]

"Hong Kong" or "HK"	the Hong Kong Special Administrative Region of the PRC;

[**REDACTED**]

"Hong Kong Takeovers Code" or "Takeovers Code"	Codes on Takeovers and Mergers and Share Buy-backs issued by the SFC;

[**REDACTED**]

"IFRS"	International Financial Reporting Standards, which include standards, amendments and interpretations promulgated by the International Accounting Standards Board and the International Accounting Standards and interpretation issued by the International Accounting Standards Committee

"Independent Third Party(ies)"	individuals or company(ies), who or which, to the best of our Directors' knowledge, information and belief, having made all reasonable enquiries, is not a connected person of our Company within the meaning of the Listing Rules;

[**REDACTED**]

"Jiarun Hechuang"	Zhuhai Jiarun Hechuang Technology Development Partnership (Limited Partnership)* (珠海嘉潤合創科技發展合夥企業(有限合夥)) (formerly known as Tianjin Jiarun Hechuang Technology Development Partnership (Limited Partnership)* (天津嘉潤合創科技發展合夥企業(有限合夥)), a limited partnership established in the PRC on January 11, 2021, which is owned as to 99% and 1% by Shuimu Medical Technology as its limited partner, and Renxiang Biotechnology as its general partner, respectively, and is one of our Controlling Shareholders;

"Jiarun Tongchuang"	Zhuhai Jiarun Tongchuang Technology Development Partnership (Limited Partnership)* (珠海嘉潤同創科技發展合夥企業(有限合夥)) (formerly known as Tianjin Jiarun Tongchuang Technology Development Partnership (Limited Partnership)* (天津嘉潤同創科技發展合夥企業(有限合夥)), a limited partnership established in the PRC on April 4, 2018, which is owned as to 99% and 1% by China True Health Medical as its limited partner, and Renxiang Biotechnology as its general partner, respectively, and is one of our Controlling Shareholders;
"Jiarun Xinchuang"	Zhuhai Jiarun Xinchuang Technology Development Partnership (Limited Partnership)* (珠海嘉潤新創科技發展合夥企業(有限合夥)) (formerly known as Tianjin Jiarun Xinchuang Technology Development Partnership (Limited Partnership)* (天津嘉潤新創科技發展合夥企業(有限合夥)), a limited partnership established in the PRC on December 29, 2020, which is owned as to 66.67%, 32.33%, and 1% by Ms. Xu Yan (徐岩), an Independent Third Party, and Ms. Cheong as its limited partners, and Renxiang Biotechnology as its general partner, respectively, and is one of our Controlling Shareholders;

[**REDACTED**]

"Joint Sponsors"	China International Capital Corporation Hong Kong Securities Limited and DBS Asia Capital Limited;
"Latest Practicable Date"	November 30, 2025, being the latest practicable date for ascertaining certain information in this document before its publication;

[**REDACTED**]

"Listing Committee"	the listing sub-committee of the board of directors of the Stock Exchange;

[**REDACTED**]

"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time;
"Macao" or "Macau"	the Macau Special Administrative Region of the PRC;
"Main Board"	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operates in parallel with the Growth Enterprise Market of the Stock Exchange;
"MIIT"	the Ministry of Industry and Information Technology (中華人民共和國工業和信息化部);
"Ministry of Finance" or "MOF"	Ministry of Finance of the PRC (中華人民共和國財政部);
"MOFCOM"	Ministry of Commerce of the PRC (中華人民共和國商務部);
"MOP"	Macau Pataca, the lawful currency of Macau;
"Ms. Cheong"	Ms. Cheong Hou Iam (張昊任), our founder, our executive Director, the chairperson of our Board, the general manager of our Company and one of our Controlling Shareholders;
"MST"	Ministry of Science and Technology of the PRC (中華人民共和國科學技術部);
"NDRC"	National Development and Reform Commission of the PRC (中華人民共和國國家發展和改革委員會);
"NHC"	National Health Commission of the PRC (中華人民共和國國家衛生健康委員會);

"NMPA"	National Medical Products Administration (國家藥品監督管理局);
"Nomination Committee"	the nomination committee of our Board;

[**REDACTED**]

"PBOC"	the People's Bank of China (中國人民銀行), the central bank of the PRC;

"PRC Company Law"	the Company Law of the PRC (《中華人民共和國公司法》), enacted by the Standing Committee of the Eighth National People's Congress on December 29, 1993 and effective on July 1, 1994, and subsequently [**REDACTED**] on December 25, 1999, August 28, 2004, October 27, 2005, December 28, 2013, October 26, 2018 and December 29, 2023, as amended, supplemented or otherwise modified from time to time;
"PRC government"	the central government of the PRC and all governmental subdivisions (including provincial, municipal and other regional or local government entities) and organizations of such government or, as the context requires, any of them;
"PRC Legal Advisors"	Beijing DeHeng Law Offices, our legal advisors as to PRC laws in connection with the [**REDACTED**];
"Pre-[**REDACTED**] Employee Incentive Scheme"	the pre-[**REDACTED**] employee incentive scheme adopted by our Company, and the principal terms of which are set out in the section headed "Appendix VI—Statutory and General Information—E. Employee Incentive Scheme" to this document;
"Pre-[**REDACTED**] Investment(s)"	the pre-[**REDACTED**] investment(s) in our Company, details of which are set out in "History and Corporate Structure—Pre-[**REDACTED**] Investments" in this document;

[**REDACTED**]

"Remuneration and Appraisal Committee"	the remuneration and appraisal committee of our Board;
"Renminbi" or "RMB"	the lawful currency of the PRC;
"Renxiang Biotechnology"	Guangdong Hengqin Renxiang Biotechnology Co., Ltd.* (廣東橫琴任祥生物科技有限公司), a limited liability company established in the PRC on April 30, 2019, which is owned as to 99.99% and 0.01% by our Ms. Cheong and Ms. Yu Lili (于莉莉), an Independent Third Party, respectively, and is one of our Controlling Shareholders;
"Renyang Biotechnology"	Guangdong Hengqin Renyang Biotechnology Center (Limited Partnership)* (廣東橫琴任陽生物科技中心(有限合夥)), a limited partnership established in the PRC on May 9, 2019, which is owned as to 99% and 1% by China True Health Medical as its limited partner, and Renxiang Biotechnology as its general partner, respectively, and is one of our Controlling Shareholders;
"Reporting Accountants"	Ernst & Young, the reporting accountants of our Company;
"R&D"	research and development;
"Regulation S"	Regulation S under the U.S. Securities Act;
"SAFE"	the State Administration of Foreign Exchange of the PRC (中華人民共和國外匯管理局);
"SAMR"	the State Administration of Market Regulation of the PRC (中華人民共和國國家市場監督管理總局);
"SAT"	the State Administration of Taxation of the PRC (中華人民共和國國家稅務總局);
"SCNPC"	the Standing Committee of the National People's Congress (全國人民代表大會常務委員會);
"SFC"	the Securities and Futures Commission of Hong Kong;
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time;

"Share(s)"	ordinary share(s) in the capital of our Company with a nominal value of RMB1.00 each, comprising Domestic Unlisted Shares and H Shares;
"Shareholder(s)"	holder(s) of our Share(s);
"Shuimu Medical Technology"	China Shui Mu Medical Technology Company Limited (中國水木醫療科技有限公司), a limited liability company established in Macau on May 31, 2019, which is owned as to 96.67% and 3.33% by Ms. Cheong and Mr. Cheong Kam Leng (張錦鈴), father of Ms. Cheong, respectively, and is one of our Controlling Shareholders;
"Sophisticated Investor(s)"	has the meaning ascribed to it under Chapter 2.3 of the Guide;
"Sponsor-[**REDACTED**]"	[**REDACTED**]

[**REDACTED**]

"State Council"	the State Council of the PRC (中華人民共和國國務院);
"Stock Exchange"	The Stock Exchange of Hong Kong Limited, a wholly owned subsidiary of Hong Kong Exchanges and Clearing Limited;
"subsidiary(ies)"	has the meaning ascribed to it under the Listing Rules;
"substantial shareholder(s)"	has the meaning ascribed to it under the Listing Rules;
"Track Record Period"	the years ended December 31, 2023 and 2024, and the six months ended June 30, 2025;
"Trial Measures"	the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (境內企業境外發行證券和上市管理試行辦法), promulgated by the CSRC on February 17, 2023;
"True Health (Beijing)"	True Health (Beijing) Medical Technology Co., Ltd.* (真健康(北京)醫療科技有限公司) (formerly known as Kangren (Beijing) Medical Technology Co., Ltd.* (康任(北京)醫療科技有限公司)), a limited liability company established in the PRC on November 21, 2022 and a direct wholly-owned subsidiary of our Company;

"True Health (Guangdong Hengqin)"	True Health (Guangdong Hengqin) Medical Device Co., Ltd.* (真健康(廣東橫琴)醫療設備有限公司) (formerly known as True Health (Zhuhai) Medical Technology Co., Ltd.* (真健康(珠海)醫療科技有限公司)), a limited liability company established in the PRC on July 26, 2021 and a direct wholly-owned subsidiary of our Company;
"True Health (Hainan)"	True Health (Hainan) Medical Technology Co., Ltd.* (真健康(海南)醫療科技有限公司), a limited liability company established in the PRC on November 10, 2021 and a direct wholly-owned subsidiary of our Company;
"True Health (HK)"	True Health (HK) Medi-Technology Co., Limited (真健康(香港)醫療科技有限公司), a limited liability company established in Hong Kong on August 19, 2025 and a direct wholly-owned subsidiary of our Company;
"True Health (Macau)"	China True Health Technology Co., Ltd. (中國真健康科技有限公司) (formerly known as China Fu Dan Medical Technology Investment Ltd. (中國復旦醫療科技投資有限公司), a limited liability company established in Macau on August 3, 2021 and a direct wholly-owned subsidiary of our Company;
"True Health Jiesheng (Guangdong Hengqin)"	True Health Jiesheng (Guangdong Hengqin) Medical Technology Co., Ltd.* (真健康捷盛(廣東橫琴)醫療科技有限公司), a limited liability company established in the PRC on December 6, 2024 and a direct wholly-owned subsidiary of our Company;

[**REDACTED**]

"U.S." or "United States"	the United States of America, its territories, its possessions and all areas subject to its jurisdiction;
"U.S. persons"	U.S. persons as defined in Regulation S;
"U.S. Securities Act"	United States Securities Act of 1933, as amended, supplemented or otherwise modified from time to time;

"VAT"	the PRC value-added tax;
"Xinhui Runkang"	Xinhui Runkang (Zhuhai Hengqin) Investment Consulting Center (Limited Partnership)* (欣慧潤康(珠海橫琴)投資諮詢中心(有限合夥)), a limited partnership established in the PRC on August 13, 2021, which is owned as to 26%, 25%, 10%, 9%, and 30%, by Ji Caixia (季彩霞), Li Yi (李毅), Huang Yin (黃茵), and Zhang Dongwu (張東武) as its limited partners, who are Independent Third Parties, and Renxiang Biotechnology as its general partner, respectively, and is one of our Controlling Shareholders;
"Zhenyida (Beijing)"	Zhenyida (Beijing) Medical Technology Co., Ltd.* (真易達(北京)醫療科技有限公司), a limited company established in the PRC on September 5, 2023 and a direct wholly-owned subsidiary of our Company, which was subsequently deregistered on May 29, 2025;
"Zhenyida (Huzhou)"	Zhenyida (Huzhou) Medical Technology Co., Ltd.* (真易達(湖州)醫療科技有限公司), a limited liability company established in the PRC on March 1, 2023 and a direct wholly-owned subsidiary of our Company;
"Zhuhai Jiansheng"	Zhuhai Jiansheng Medical Technology Co., Ltd.* (珠海健升醫療科技有限公司), a limited company established in the PRC on July 28, 2022 and a direct wholly-owned subsidiary of our Company, which was subsequently deregistered on November 15, 2024;
"Zhuhai Meijirui"	Zhuhai Meijirui Medical Technology Partnership (Limited Partnership)* (珠海美吉睿醫療科技合夥企業(有限合夥)), a limited partnership established in the PRC on June 15, 2022, which is our employee shareholding platform and is owned as to 97%, 1%, 1%, and 1% by Ms. Cheong, Ms. Guo Jian (郭健), our executive Director and vice general manager of our Company, and Mr. Shi Jipeng (史紀鵬), our R&D director, as its limited partners and Renxiang Biotechnology as its general partner, respectively, and is one of our Controlling Shareholders. For details, see "History and Corporate Structure—Our Employee Shareholding Platform" and "Statutory and General Information—E. Pre-[**REDACTED**] Employee Incentive Scheme" in Appendix VI to this document;

"Zhuhai Yudao"	Zhuhai Yudao Medical Technology Co., Ltd.* (珠海譽刀醫療科技有限公司), a limited company established in the PRC on July 28, 2022 and an indirect wholly-owned subsidiary of our Company, which was subsequently deregistered on January 24, 2024; and
"%"	per cent.

Unless otherwise specified, all references to any shareholdings in our Company following the completion of the [**REDACTED**] *assume that the* [**REDACTED**] *is not exercised.*

Unless the content otherwise requires, references to "2023" and "2024" in this document refer to our financial year ended December 31 of such year.

For ease of reference, the names of Chinese laws and regulations, governmental authorities, institutions, natural persons or other entities (including certain of our subsidiaries) have been included in the document in both the Chinese and English languages and in the event of any inconsistency, the Chinese versions shall prevail. English translations of company names which are marked with "" and other terms from the Chinese language are provided for identification purposes only.*

Certain amounts and percentage figures included in this document were subjected to rounding adjustments. Accordingly, figures shown as totals in certain tables may not be arithmetic aggregation of the figures preceding them.

For the purpose of this document, references to "provinces" of China include provinces, municipalities under direct administration of the central government and provincial-level autonomous regions.